AUCTUS SIGNED TO SELL PHARMALEX, THE PHARMACEUTICAL BUY-AND-BUILD PLATFORM
Sale of PharmaLex Group to NYSE-listed AmerisourceBergen Corporation.
Funds advised by AUCTUS Capital Partners AG sell a majority stake in the leading pharma services group PharmaLex to AmerisourceBergen Corporation. During the 8 years of AUCTUS investment and a successful buy-and-build strategy, PharmaLex has shown a double digit organic growth that was seconded by a decisive international acquisition strategy. 37 add-ons that supported the group in terms of rounding up the product portfolio, global reach and coverage of key clients helped PharmaLex to become the leading provider of specialized services for the life sciences industry.
PharmaLex is a global team of scientific, regulatory, and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle. The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations.
Headquartered in Germany, PharmaLex has developed its global reach with a significant footprint in Europe and the U.S. and a growing presence in other parts of the world.
AmerisourceBergen’s acquisition of the PharmaLex Group will advance the company’s role as partner of choice for pharmaceutical partners by enhancing their global solutions to support clients across the pharmaceutical development and commercialization journey.
Dr. Nicolas Himmelmann, Partner with Auctus comments: „Over almost a decade we have helped PharmaLex to become the preferred partner for the global Biopharma industry plus to shape its profile as the centre of gravity attracting further specialists in the fragmented pharmaservice market to join the integrated group, paving the future growth path.“
The transaction is expected to close by March 2023. On the part of AUCTUS, the platform was managed by Dr. Nicolas Himmelmann and Benjamin Seifert.
AUCTUS is the most active investment company for small- and medium-sized companies. With over 350 investments in the last 20 years, we are the definite No. 1 in Germany. Our successful work is regularly rewarded with prestigious awards and top international rankings. The focus of our investments is on majority holdings in companies with annual sales of between EUR 10 million and EUR 150 million. AUCTUS stands for sustainable organic and also inorganic growth by acquisitions. We achieve this in a trustful partnership together with the management of our companies. We are specialized in building successful medium-sized company groups – We create market leaders. The more than 20 experienced AUCTUS investment experts currently manage around 47 platform investments from various sectors of the economy. The sum of the platform investments with a total of more than 150 individual companies achieves annual sales of far more than € 2 billion. Sales and results have been growing at >10% per year for years.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.